Unlike in NSCLC, G12C mutations represent only a minor fraction of KRAS mutations detected in PDAC, yet this therapeutic approach has been evaluated in gastrointestinal carcinomas including pancreatic cancer, albeit with limited success. This evidence concerns the gene KRAS and familial pancreatic carcinoma.